Carbidopa and Benserazide
They are extra-cerebral dopa-decarboxylase inhibitors; they onot penetrate blood brain barrier and donot inhibit conversion of levodopa to Dopamine in brain. Administered along with levodopa, they increase its t1/2 in the periphery and make more of it available to cross blood brain barrier to reach its site of action. Benefits thus obtained are : a) Dose of levodopa is reduced to 1/4. b) Therapeutic doses of levodopa can be attained quickly. c)Cardiac complication are reduced.Parkinson’s disease and syndrome, patients not responding adequately to levodopa alone.
Same as that for Levodopa.
Same as that for Levodopa.